
Patent Claims

1. A compound of formula I



I

in the form of a single stereoisomer in crystalline form selected from the group consisting of:

crystalline Form 1, which is characterized by an X-ray powder diffraction pattern having at least two peaks 2-theta at (degrees, ±0.2): 10.6, 11.1, 12.0, 14.3, 15.1, 16.1, or 21.1;

crystalline Form 2, which is an *n*-butanol solvate characterized by an X-ray powder diffraction pattern having at least two peaks 2-theta at (degrees, ±0.2): 9.8, 11.1, 13.1, 14.1, 17.6, 19.7, or 22.2;

an acetate in crystalline Form A, which is characterized by an X-ray powder diffraction pattern having at least four peaks 2-theta at (degrees, ±0.2): 7.0, 7.7, 11.6, 12.1, 12.6, 13.5, 13.7, 15.4, 15.7, 16.9, 17.3, 19.0, 19.9, 21.1, 23.4, 24.2, or 24.4;

an acetate in crystalline Form B, which is characterized by an X-ray powder diffraction pattern having at least four peaks 2-theta at (degrees, ±0.2): 10.3, 10.7, 12.7, 14.3, 15.5, 16.0, 17.2, 19.5, 20.6, 22.9;

an L-lactate in crystalline Form 1, which is characterized by an X-ray powder diffraction pattern having at least two peaks 2-theta at (degrees, ±0.2): 7.0, 11.6, 12.0, 12.5, 13.4, 13.6, 13.9, 15.3, 16.8, 18.8, 19.5, 19.8, 20.9, 23.3, 23.9, or 24.2; and

a hydrogenmaleate in crystalline Form 1, which is characterized by an X-ray powder diffraction pattern having at least two peaks 2-theta at (degrees, ±0.2): 7.0, 11.3, 11.7, 12.5, 13.5, 13.8, 15.3, 16.7, 18.3, 19.4, 19.7, 21.1, 22.2, 23.8, or 23.9.

.

2. A compound according to claim 1, which is 14-*O*-{[(1*R*,2*R*,4*R*)-4-amino-2-hydroxy-cyclohexylsulfanyl]-acetyl}-mutilin in crystalline Form 1, characterized by an X-ray powder diffraction pattern ~~with~~ having peaks 2-theta at (degrees, ±0.2): 10.6, 11.1, 12.0, 14.3, 15.1, 16.1, and 21.1.

3. A compound according to claim 1, which is 14-*O*-{[(1*R*,2*R*,4*R*)-4-amino-2-hydroxy-cyclohexylsulfanyl]-acetyl}-mutilin in crystalline Form 2 in the form of a *n*-butanol solvate, characterized by an X-ray powder diffraction pattern ~~with~~ having peaks 2-theta at (degrees, ±0.2): 9.8, 11.1, 13.1, 14.1, 17.6, 19.7, and 22.2.

~~4. A compound of formula I as defined in claim 1 in the form of a single stereoisomer in the form of a crystalline salt.~~

~~5. A crystalline salt according to claim 4, which is an acetate, lactate or hydrogenmaleate.~~

~~6~~4. A compound according to ~~any one of claims 4 or 5~~claim 1, which is selected from the group consisting of

14-*O*-{[(1*R*,2*R*,4*R*)-4-amino-2-hydroxy-cyclohexylsulfanyl]-acetyl}-mutilin acetate in crystalline Form A, characterized by an X-ray powder diffraction pattern ~~with~~ having peaks 2-theta at (degrees, ±0.2): 7.0, 7.7, 11.6, 12.1, 12.6, 13.5, 13.7, 15.4, 15.7, 16.9, 17.3, 19.0, 19.9, 21.1, 23.4, 24.2, and 24.4;

14-*O*-{[(1*R*,2*R*,4*R*)-4-amino-2-hydroxy-cyclohexylsulfanyl]-acetyl}-mutilin acetate in crystalline Form B, characterized by an X-ray powder diffraction pattern ~~with~~ having peaks 2-theta at (degrees, ±0.2): 10.3, 10.7, 12.7, 14.3, 15.5, 16.0, 17.2, 19.5, 20.6, and 22.9;

14-*O*-{[(1*R*,2*R*,4*R*)-4-amino-2-hydroxy-cyclohexylsulfanyl]-acetyl}-mutilin L-lactate in crystalline Form 1, characterized by an X-ray powder diffraction pattern ~~with~~ having peaks 2-theta at (degrees, ±0.2): 7.0, 11.6, 12.0, 12.5, 13.4, 13.6, 13.9, 15.3, 16.8, 18.8, 19.5, 19.8, 20.9, 23.3, 23.9, and 24.2; and

14-*O*-{[(1*R*,2*R*,4*R*)-4-amino-2-hydroxy-cyclohexylsulfanyl]-acetyl}-mutilin hydrogenmaleate in crystalline Form 1, characterized by an X-ray powder diffraction

pattern ~~with~~ having peaks 2-theta at (degrees, ±0.2): 7.0, 11.3, 11.7, 12.5, 13.5, 13.8, 15.3, 16.7, 18.3, 19.4, 19.7, 21.1, 22.2, 23.8, and 23.9.